An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Prothena plc (NASDAQ:PRTA) will report its first quarter 2024 financial results on May 8, 2024, after the close of the U.S. financial markets. The company, a late-stage clinical biotechnology firm focusing on investigational therapeutics, will not host a conference call along with the results release.
Prothena plc (NASDAQ:PRTA) comunicherà i risultati finanziari del primo trimestre del 2024 l'8 maggio 2024, dopo la chiusura dei mercati finanziari statunitensi. L'azienda, che è una società biotecnologica in fase avanzata di sviluppo clinico e si concentra su terapeutici sperimentali, non organizzerà una conferenza telefonica in occasione della pubblicazione dei risultati.
Prothena plc (NASDAQ:PRTA) reportará sus resultados financieros del primer trimestre de 2024 el 8 de mayo de 2024, tras el cierre de los mercados financieros de EE. UU. La compañía, una empresa biotecnológica en etapa avanzada de desarrollo clínico enfocada en terapéuticos en investigación, no realizará una conferencia telefónica junto con la publicación de los resultados.
Prothena plc (NASDAQ: PRTA)는 2024년 5월 8일 미국 금융 시장의 마감 후 2024년 첫 번째 분기 재무 결과를 보고할 예정입니다. 이 회사는 실험적 치료법에 중점을 둔 후기 임상 단계의 생명공학 회사로, 결과 발표와 함께 컨퍼런스 콜을 개최하지 않을 것입니다.
Prothena plc (NASDAQ:PRTA) annoncera ses résultats financiers pour le premier trimestre 2024 le 8 mai 2024, après la fermeture des marchés financiers américains. L'entreprise, qui est une société biotechnologique en phase clinique avancée se concentrant sur les thérapeutiques en investigation, ne tiendra pas de conférence téléphonique lors de la publication des résultats.
Prothena plc (NASDAQ:PRTA) wird am 8. Mai 2024 nach Börsenschluss in den USA die Finanzergebnisse für das erste Quartal 2024 bekannt geben. Das Unternehmen, ein biotechnologisches Unternehmen in späten klinischen Entwicklungsphasen, das sich auf die Erforschung neuer therapeutischer Ansätze konzentriert, wird keine Telefonkonferenz im Zusammenhang mit der Veröffentlichung der Ergebnisse abhalten.
Positive
None.
Negative
None.
DUBLIN, Ireland--(BUSINESS WIRE)--
Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on protein dysregulation expertise, today announced that it will report its first quarter 2024 financial results on Wednesday, May 8, 2024, after the close of the U.S. financial markets.
Consistent with past practice, the Company will not be conducting a conference call in conjunction with the financial results release on May 8.
About Prothena
Prothena Corporation plc is a late-stage clinical biotechnology company with expertise in protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare peripheral amyloid diseases. Fueled by its deep scientific expertise built over decades of research, Prothena is advancing a pipeline of therapeutic candidates for a number of indications and novel targets for which its ability to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins can be leveraged. Prothena’s pipeline includes both wholly-owned and partnered programs being developed for the potential treatment of diseases including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a number of other neurodegenerative diseases. For more information, please visit the Company’s website at www.prothena.com and follow the Company on Twitter @ProthenaCorp.
